Ann: Phase 1 CF33-hNIS Study Update - Positive Early Signals, page-159

The vector / cell manufacturing plant is part of the deal as without it Acer-Cel can't be done. There is a shortage of suitable re-programmable cell manufacturing sites, currently a waiting time up to 2 years for new "wannabe" CAR-Ts to get their cells.

The problem is not grabbing incredible bargains, the problem is the sales team ( Shah, Eckstein, Hopper ) to get out there and to sell it to investors and big pharma.

At the JPM conference Monil and Co should have taken over after LC's presentation and should have said something like that:

M/E/H: Normally you pay up to USD 10b for pipelines and data like that but today, we have a special offer for the attendees only. To get a stake in IMU you would take the sp up to 30c but today we offer you a 500m share stake at 15c. That means a huge investment opportunity for the hottest data any oncology platform can offer. Here is where you sign. This offer only applies to the first 10 funds and is not available online or at the ASX.

But no, they were not there. LC isn't hired to sell the data, it's the job of MEH and so far the 3 "wise" men have bitterly failed to put some decent value on what the incredible science team has delivered. Same applies to CHM and RAD.

GLTA